^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Adrenergic uptake inhibitor

    Related drugs:
    3d
    Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, Necmettin Erbakan University | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Nov 2026
    Enrollment closed • Trial primary completion date
    18d
    Atomoxetine attenuates methotrexate-induced lung injury in rats implicating TLR4/NF-κB and Bax/Bcl-2/caspase-3 signaling cascades: a study based on molecular docking and experimental validation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    All of the aforementioned biochemical and histological abnormalities were greatly improved with ATOM. ATOM significantly improved MTX-induced pulmonary injury by suppressing TLR4/MYD88/NF-κB p65 and caspase-3-mediated apoptotic signaling pathways.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TLR4 (Toll Like Receptor 4)
    |
    methotrexate
    19d
    Imipramine Targets Apoptosis, Metastasis, and EGFR/SRC-mediated EMT in Oral Cancer Cells. (PubMed, Anticancer Res)
    Imipramine exhibits potent anti-OC activity by inducing apoptosis, inhibiting metastasis, and suppressing EMT, supporting its potential as a repurposed therapeutic agent.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • FASLG (Fas ligand) • MMP2 (Matrix metallopeptidase 2) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • XIAP (X-Linked Inhibitor Of Apoptosis) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    imipramine
    2ms
    116130: Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinsons disease: a multi-center and multi-modal approach. (2024-516756-18-00)
    P2/3, N=20, Recruiting, Stichting Radboud universitair medisch centrum | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov)
    P3, N=60, Recruiting, Radboud University Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    FORWARD: Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design (clinicaltrials.gov)
    P3, N=620, Recruiting, Axsome Therapeutics, Inc.
    New P3 trial
    4ms
    Populational pharmacokinetics of methylphenidate hydrochloride extended-release tablets in Chinese school-age children with attention-deficit/hyperactivity disorder (ChiCTR2500115500)
    P=N/A, N=60, Completed, Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University
    New trial
    4ms
    AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov)
    P3, N=60, Not yet recruiting, Radboud University Medical Center
    New P3 trial
    5ms
    Repositioning serotonergic antagonists as therapeutic agents in gastric cancer: induction of apoptosis, inhibition of cell migration, and cell cycle arrest in AGS cells. (PubMed, Cytotechnology)
    Imipramine induced G1/S phase arrest, whereas tropisetron, ketanserin, and cyproheptadine increased the sub-G1 cell population. Gene expression analysis revealed decreased Bcl-2 and PCNA levels and increased Bax expression.These findings suggest the potential of tropisetron, imipramine, ketanserin, and cyproheptadine as repurposed therapeutic agents for gastric cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • SLC6A4 (Solute Carrier Family 6 Member 4)
    |
    imipramine
    5ms
    The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans (clinicaltrials.gov)
    P2, N=48, Recruiting, VA Office of Research and Development | N=24 --> 48
    Enrollment change
    |
    imipramine
    6ms
    Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov)
    P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45
    Trial completion • Enrollment change
    6ms
    Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. (PubMed, Lab Invest)
    These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    HER-2 expression
    |
    imipramine